Literature DB >> 27586499

Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Luis V Syro1, Fabio Rotondo2, Carlos A Serna3, Leon D Ortiz4, Kalman Kovacs2.   

Abstract

INTRODUCTION: Histologic, immunohistochemical and electron microscopic studies have provided conclusive evidence that a marked diversity exists between tumors which secrete growth hormone (GH) in excess. GH cell hyperplasia can also be associated with acromegaly in patients with extrapituitary GH-releasing hormone secreting tumors or in familial pituitary tumor syndromes.
MATERIALS AND METHODS: A literature search was performed for information regarding pathology, GH-producing tumors and acromegaly.
RESULTS: This review summarizes the current knowledge on the morphology of GH-producing and silent GH adenomas, as well as GH hyperplasia of the pituitary.
CONCLUSION: The importance of morphologic classification and identification of different subgroups of patients with GH-producing adenomas and their impact on clinical management is discussed.

Entities:  

Keywords:  Acromegaly; Classification; Diagnosis; Immunohistochemistry; Pathology; Pituitary neoplasms

Mesh:

Substances:

Year:  2017        PMID: 27586499     DOI: 10.1007/s11102-016-0748-8

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  69 in total

Review 1.  Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.

Authors:  Karen Gomez-Hernandez; Shereen Ezzat; Sylvia L Asa; Özgür Mete
Journal:  Turk Patoloji Derg       Date:  2015

2.  Ultrastructural and immunoelectron microscopic study of three unusual plurihormonal pituitary adenomas.

Authors:  S Vidal; L Syro; E Horvath; H Uribe; K Kovacs
Journal:  Ultrastruct Pathol       Date:  1999 May-Jun       Impact factor: 1.094

Review 3.  Growth hormone-secreting adenomas: pathology and cell biology.

Authors:  M Beatriz S Lopes
Journal:  Neurosurg Focus       Date:  2010-10       Impact factor: 4.047

Review 4.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

Review 5.  Treatment of acromegaly in the era of personalized and predictive medicine.

Authors:  Manuel Puig Domingo
Journal:  Clin Endocrinol (Oxf)       Date:  2015-03-05       Impact factor: 3.478

Review 6.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

7.  The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma.

Authors:  Stine L Fougner; Olivera Casar Borota; Jens Petter Berg; John K Hald; Jon Ramm-Pettersen; Jens Bollerslev
Journal:  Clin Endocrinol (Oxf)       Date:  2007-10-17       Impact factor: 3.478

8.  Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.

Authors:  Jessica Brzana; Chris G Yedinak; Sakir H Gultekin; Johnny B Delashaw; Maria Fleseriu
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

9.  Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.

Authors:  Donato Iacovazzo; Eivind Carlsen; Francesca Lugli; Sabrina Chiloiro; Serena Piacentini; Antonio Bianchi; Antonella Giampietro; Marilda Mormando; Andrew J Clear; Francesco Doglietto; Carmelo Anile; Giulio Maira; Libero Lauriola; Guido Rindi; Federico Roncaroli; Alfredo Pontecorvi; Márta Korbonits; Laura De Marinis
Journal:  Eur J Endocrinol       Date:  2015-11-19       Impact factor: 6.664

10.  Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.

Authors:  Y Greenman; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

View more
  11 in total

Review 1.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

2.  Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes.

Authors:  Yuichi Nagata; Naoko Inoshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Hiroshi Nishioka; Takeo Iwata; Katsuhiko Yoshimoto; Shozo Yamada
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

3.  Aggressive somatotrophinomas lacking clinical symptoms: neurosurgical management.

Authors:  Mario Giordano; Amir Samii; Rudolf Fahlbusch
Journal:  Neurosurg Rev       Date:  2017-12-30       Impact factor: 3.042

4.  Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Elena Varlamov; Chris G Yedinak; Justin S Cetas; Shirley McCartney; Aclan Dogan; Maria Fleseriu
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

Review 5.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

6.  DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Nan Deng; Evelyn Ding; Masaaki Yamamoto; Adam Mamelak; Vera Chesnokova; Artak Labadzhyan; Shlomo Melmed
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

7.  Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.

Authors:  Julieann C Lee; Melike Pekmezci; Jonathan L Lavezo; Hannes Vogel; Laurence Katznelson; Merav Fraenkel; Griffith Harsh; Mohanpal Dulai; Arie Perry; Tarik Tihan
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

Review 8.  The Clinicopathological Spectrum of Acromegaly.

Authors:  Amit Akirov; Sylvia L Asa; Lama Amer; Ilan Shimon; Shereen Ezzat
Journal:  J Clin Med       Date:  2019-11-13       Impact factor: 4.241

9.  Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly.

Authors:  Jiri Soukup; Helena Hornychova; Monika Manethova; Kvetoslava Michalova; Ludmila Michnova; Lenka Popovska; Veronika Skarkova; Tomas Cesak; David Netuka; Ales Ryska; Jan Cap; Václav Hána; Václav Hána; Michal Kršek; Eva Dvořáková; Michal Krčma; Ivica Lazurova; Věra Olšovská; Karel Starý; Peter Vaňuga; Filip Gabalec
Journal:  J Cell Mol Med       Date:  2021-01-24       Impact factor: 5.310

Review 10.  Updates in Diagnosis and Treatment of Acromegaly.

Authors:  Roula Zahr; Maria Fleseriu
Journal:  Eur Endocrinol       Date:  2018-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.